Tag Archives: Nano-liposomal haematococcus astaxanthin. Anti-oxidation

PuriActives® BioFuco™ Powder

Posted on by

PuriActives® BioFuco™ Powder

A Microbiome-Friendly Prebiotic Powder Blend

A tri-saccharide system for skin and scalp microbiome balance

INCI: Biosaccharide Gum-1 · Xylitol · Lactitol

Microbiome balance · Barrier & hydration · Smart powder format

Product Technology & Market Introduction · Cosmetic Active Ingredient

01 · SKIN ECOLOGY

The Next Logic of Skincare: Skin Is an Ecosystem

Skin is more than a physical barrier — it is an ecosystem built by microorganisms, sebum, water, and immune cells together. Resident flora occupy ecological niches, produce antimicrobial molecules, and “educate” the immune system: they are the first “living line of defense” of skin homeostasis.

When the flora falls out of balance (dysbiosis), dryness, sensitivity, breakouts, and dandruff follow — the answer is to restore balance, not to eliminate indiscriminately.

Dryness & flaking · Sensitivity & redness · Breakouts · Dandruff— all are scientifically linked to microbiome imbalance

106microorganisms / cm²Order of magnitude of microbial density on healthy skin ≈1,000bacterial species identified on human skinDiversity is closely tied to skin health

Sources: Grice & Segre, Nat Rev Microbiol, 2011; Byrd et al., Nat Rev Microbiol, 2018.

02 · WHY THE MICROBIOME

From “Killing” to “Nurturing”: The Shift Toward Microbiome Balance

Traditional Antimicrobial Logic｜KILL THEM ALL

Broad-spectrum antimicrobials remove microbes indiscriminately; resident and pathogenic flora are damaged alike; the ecological vacuum lets pathogens rebound faster; barrier and flora homeostasis are repeatedly disrupted.

Microbiome Balance Logic｜BALANCE THE ECOSYSTEM

Provide sugar substrates usable by resident flora; selectively limit pathogen adhesion and biofilms; restore the natural balance of niche competition; a better microenvironment builds a stronger barrier.

Sources: Byrd et al., Nat Rev Microbiol, 2018; Katsuyama et al., J Dermatol Sci, 2005.

03 · PRODUCT CONCEPT

BioFuco™ Powder: A Tri-Saccharide Prebiotic Active

Biosaccharide Gum-1｜A Fucose-Rich Polysaccharide

A fermentation-derived polysaccharide. Film-forming water lock for lasting hydration; soothing and skin-friendly with high skin affinity; enhances formulation sensory feel.

Xylitol｜A Prebiotic Five-Carbon Sugar Alcohol

A prebiotic pentitol. A selective substrate for resident flora; upregulates filaggrin to support the barrier; limits pathogen adhesion and biofilm formation.

Lactitol｜A Prebiotic Disaccharide Alcohol

A prebiotic disaccharide polyol. Selectively utilized by beneficial bacteria; a multi-hydroxyl hydrating structure; improves scalp and skin comfort.

Polysaccharide network × prebiotic sugar alcohols × microbiome modulation — not a simple blend, but a synergistic active system designed around the skin ecosystem.

PositioningMicrobiome-friendly activePrebiotic skin-conditioning system Technical ProfileFermentation biotechnologyPreservative-free powder

04 · SYNERGY SYSTEM

The Tri-Saccharide System: One Synergistic Eco-Active

Microbiome Modulation

Selectively feeds resident flora while restraining opportunistic pathogens.

Barrier Support

Xylitol upregulates filaggrin and reduces TEWL.

Lasting Hydration

Film-forming + humectant sugars + endogenous NMF.

Soothing Comfort

The fucose-rich polysaccharide soothes sensitive, reactive skin.

The synergy logic is based on published research evidence for each component; see the evidence page and source notes.

05 · PREBIOTIC MODULATION

Selective Prebiotics: Feed the Residents, Restrain the Opportunists

Staphylococcus epidermidis

Resident flora · produces antimicrobial peptides · maintains homeostasis

1% xylitol significantly promotes growth; higher growth rate in pure culture (p < 0.001).

Staphylococcus aureus

Opportunistic pathogen · linked to atopic skin concerns · can form biofilms

5% xylitol significantly inhibits growth; growth suppressed in pure culture (p < 0.001).

Cutibacterium acnes

Common in sebum-rich areas · overgrowth linked to breakouts

5% xylitol significantly inhibits growth; both tested strains suppressed (p < 0.005–0.001).

Mechanism: xylitol is difficult for opportunistic pathogens such as S. aureus to ferment, yet can be metabolized by specific resident flora; it also inhibits S. aureus glycocalyx synthesis and biofilm formation — the essential difference between prebiotic modulation and broad-spectrum antimicrobial action. Lactitol is likewise selectively utilized by beneficial bacteria in microbiome models.

Sources: Anglenius et al., Korean J Microbiol, 2020 (in vitro, pure culture); Katsuyama et al., J Dermatol Sci, 2005; lactitol prebiotic evidence: Björklund et al., Age, 2012 (microbiome model).

06 · REBUILDING THE NICHE

Beyond Inhibition — Rebuilding a Resident-Dominated Niche

Selectivity Is Clear

The combination inhibits biofilm formation by opportunistic S. aureus by up to 64.7%, while affecting resident S. epidermidis by only < 2.5%.

Co-Culture Confirmation

The system reversed the growth advantage of S. aureus, restoring dominance to S. epidermidis — niche competition shifted back toward health.

In-Vivo Echo

A xylitol-containing cream applied to atopic dry skin significantly reduced S. aureus colonization and improved dryness within 4 weeks.

Source: Katsuyama et al., J Dermatol Sci, 2005 (Part 2, human study).

07 · SKIN BARRIER

Microbiome → Barrier → Skin Resilience

Human evidence: barrier support (14 days, n = 12, dry skin).

TEWL ↓TEWL significantly reduced; barrier function improved Filaggrin ↑More filaggrin-positive epidermal cells (~25% vs. control) Hydration ↑Stratum corneum hydration and biomechanics improved together

A 5% glycerol + 5% xylitol formula used for 14 days: TEWL fell significantly while skin hydration, epidermal and dermal thickness, and the DEJ undulation index all rose; in-vitro data identify xylitol as the key component upregulating filaggrin expression.

In an SLS acute-irritation human model, xylitol and glycerol showed dose-dependent anti-irritant and anti-inflammatory effects — direct evidence for sensitive-skin and compromised-barrier scenarios.

Sources: Korponyai et al., Acta Derm Venereol, 2017 (in vivo); Szél et al., J Eur Acad Dermatol Venereol, 2015 (in vivo).

08 · HYDRATION

A Triple Hydration Mechanism: Film · Humectancy · NMF

8hBiosaccharide Gum-1 hydration lasts 8 hours in human testingIngredient technical dossier (in-vivo volunteer study)

01 Film-Forming — a “Breathable Moisture Film”

The high-molecular-weight polysaccharide forms a non-occlusive moisturizing film on the skin surface, slowing water loss for immediate and long-lasting hydration with a silky, non-sticky feel.

02 Humectancy — Hydrogen-Bond “Water Capture”

The multi-hydroxyl structures of xylitol and lactitol bind water molecules through hydrogen bonds, raising stratum corneum water content and maintaining dynamic moisture balance even in dry environments.

03 Endogenous NMF — Upregulating Filaggrin

Xylitol upregulates filaggrin expression in keratinocytes — filaggrin breakdown products are the primary source of natural moisturizing factor (NMF), reinforcing hydration from within rather than relying on external humectants alone.

Sources: Korponyai et al., Acta Derm Venereol, 2017; Cohen et al., J Chem Soc Faraday Trans, 1993; Biosaccharide Gum-1 ingredient technical dossier (in vivo).

09 · SOOTHING & COMFORT

The Skin-Friendly Science of a Fucose-Rich Polysaccharide

Fucose is a natural component of human glycoproteins and glycolipids — skin “recognizes” Biosaccharide Gum-1, which is naturally highly affine and highly tolerated.

This makes it a time-proven soothing ingredient for sensitive and reactive skin care.

Sources: Biosaccharide Gum-1 ingredient technical dossier (in-vivo volunteer testing); Szél et al., J Eur Acad Dermatol Venereol, 2015 (in vivo); CIR Expert Panel safety assessment of microbial polysaccharide gums.

PART II · THE SMART POWDER FORMAT

From Liquid Actives to a Smart Powder

A more stable, more convenient, more efficient delivery form for a microbiome active

10 · WHY POWDER

Why a Powder: Five Pain Points of Liquid Actives, Solved One by One

Preservative-Free Format

Low water activity inhibits microbial growth, reducing reliance on preservatives.

Easy to Store

A solid form — simply sealed at room temperature; stable in long-term inventory.

Easy to Ship

Over 95% of water weight removed; built for global supply chains.

Easy to Handle

Free-flowing and non-caking; convenient to weigh and dose in both lab and production.

Easy to Disperse

Disperses quickly and evenly in the water phase; suitable for transparent formulas as well.

Traditional Liquid Actives BIOFUCO™ POWDER
~97% water · requires a preservation system Solid composite powder · low water activity by design
Heavy to ship · shelf life challenged by microbes Light to ship · storage-friendly · flexible supply chain
Low-dose actives are hard to weigh precisely Solid dilution ensures weighing and dispersion accuracy

The format comparison is based on the typical ~97% water content of liquid products in public technical literature; actual formulation performance should be verified.

11 · SMART SOLID DILUTION

Smart Solid Dilution: Every Milligram Under Precise Control

What It Means for Formulators

  • Accurate dosing: gram-scale handling with milligram-level precision.
  • Uniform dispersion: no local concentration spikes.
  • Non-caking: free-flowing and disperses instantly in water.
  • Scalable dosing: seamless scale-up from lab to production.
  • Standardized delivery: consistent active content from batch to batch.
  • High efficacy at low dose: a 1%–2% reference use level delivers the designed activity.

Use levels are reference ranges and should be optimized against formulation goals; the solid dilution process is a product design description.

12 · SCALP MICROBIOME

The Scalp: An Ecosystem That Also Needs Balance

The microbial fingerprint of dandruff: lipophilic Malassezia rises from 46% to 74%–83%, while resident C. acnes falls from 26% to single digits — dandruff is fundamentally a flora-imbalance problem.

The cascade of imbalance: dysbiosis accompanies elevated TEWL and pH plus a compromised scalp barrier, leading to dryness, itching, flaking, and scalp sensitivity.

A new care target: maintain scalp flora homeostasis and nourish the resident ecology — the next generation of scalp care beyond “aggressive anti-dandruff.”

13 · SCALP EVIDENCE

Xylitol × Lactitol: Evidence for Scalp Hydration and Barrier

Study Design

28 volunteers (16 women / 12 men) used a xylitol–lactitol wash-and-care regimen 3 times over 10 days — shampoo 1% + conditioner 1% + leave-on product 2%, against a placebo control.

Results

Scalp hydration rose +27% immediately and held at +17% on day 10; TEWL improved by -12.7% (trend); video microscopy showed regulated desquamation and stronger scalp barrier integrity.

Implication

By restoring scalp ecological balance — feeding beneficial flora and restraining harmful flora — dryness, itching, and dandruff discomfort are relieved at the source.

14 · SKINCARE APPLICATIONS

Skincare Applications: From Concept to Everyday Formulas

Microbiome Concepts

Microbiome skincare serums · prebiotic / postbiotic creams · post-cleansing microbiome care · flora-balancing lotions

Targeted Care

Soothing care for sensitive skin · barrier-repair creams · long-lasting hydrating serums and masks · microbiome care for blemish-prone skin

Gentle Scenarios

Gentle baby and child care · hydrating soothing mists · cleansers and rinse-off products · after-sun repair gels

Positioning: a microbiome-friendly active · a prebiotic skin-conditioning systemSuitable for leave-on and rinse-off systems; the water-soluble powder fits serums, creams, masks, mists, and cleansers.

Whether for a new “flora balance” concept launch or a sensitive-skin formula that pairs soothing with barrier support, BioFuco™ Powder delivers a clear scientific narrative and formulator-friendliness through a concise INCI combination.

15 · HAIR & SCALP CARE

From Scalp Ecology to Hair Condition

Scalp MicrobiomeBalanced scalp flora Scalp BarrierScalp barrier integrity Comfort & HydrationComfort and moisture Healthy HairA healthy environment for hair

Typical Product Applications

  • Microbiome shampoos
  • Leave-on scalp serums
  • Soothing scalp mists
  • Conditioners and hair masks
  • Anti-dandruff support care
  • Products for sensitive scalps

Bonus: the film-forming property of Biosaccharide Gum-1 can remain on the hair fiber surface after rinsing, helping smooth the cuticle and enhance smoothness and shine (ingredient technical dossier).

16 · FORMULATOR-FRIENDLY

For Formulators: Usage Guide and Technical Notes

Item Recommendation
Reference use level 0.5%–2.0% (reference range; optimize per formulation goals and efficacy positioning)
Phase of addition Add to the water phase; ≤45°C for emulsion systems, room temperature for gels and aqueous systems
Dissolution & dispersion Sprinkle slowly into the water phase under stirring; disperses and dissolves within minutes; pre-disperse and sieve for transparent formulas
pH suitability 4.0–8.0 (reference range; suits mildly acidic to neutral systems)
Compatibility & compliance Good compatibility with common surfactants, thickeners, and preservation systems (reference); all three ingredients are IECIC-listed cosmetic raw materials; xylitol has been assessed by CIR

The above is a reference guide based on the ingredient’s public technical documentation and does not constitute precise process parameters; final formulation parameters should be confirmed through laboratory validation and stability testing.

17 · EVIDENCE CHAIN

The Evidence Chain: Mechanism → Evidence → Benefit

Mechanism Key Evidence (Source · Level) Cosmetic Benefit
Selective microbiome modulation 1% xylitol promotes S. epidermidis; 5% inhibits S. aureus / C. acnes — Anglenius et al., Korean J Microbiol, 2020 · in vitro Microbiome-friendly concept
Anti-biofilm & niche rebuilding Xylitol inhibits S. aureus glycocalyx and biofilms — Katsuyama et al., J Dermatol Sci, 2005 · in vitro + human; prebiotic blend inhibits S. aureus biofilms by up to 64.7% — Di Lodovico et al., Microorganisms, 2021 · in vitro Blemish-prone and sensitive skin care
Barrier strengthening Filaggrin expression up, TEWL significantly down (14 days, n=12) — Korponyai et al., Acta Derm Venereol, 2017 · human Barrier repair
Triple hydration Polysaccharide film hydrates for 8 hours — ingredient dossier · human; polyol hydrogen bonding to water — Cohen et al., 1993; filaggrin/NMF upregulation — Korponyai et al., 2017 Long-lasting hydration
Soothing & comfort Post-challenge volunteer testing confirms soothing — ingredient dossier · human; dose-dependent anti-irritation in the SLS model — Szél et al., JEADV, 2015 · human Sensitive-skin comfort
Scalp microbiome care Scalp hydration +27% (immediate) / +17% (day 10), TEWL -12.7% (day 10, n=28) — PCT/IB2004/004345 patent-family clinical data · human Scalp and hair care

In-vitro / dossier data ≠ finished-product clinical efficacy; third-party literature is for technical reference only and does not represent results for the BioFuco™ Powder finished formulation.

SUMMARY & CONTACT

Feed the beneficial flora. Balance the microbiome.

Microbiome BalanceFeed residents, restrain opportunists Barrier SupportFilaggrin · TEWL · NMF HydrationFilm + humectancy + NMF
Skin ComfortSoothing for sensitive skin Scalp CareBacked by clinical evidence Smart Powder FormatPreservative-free · easy to use

PuriActives® BioFuco™ Powder — the prebiotic powder for skin and scalp microbiome balance

PURIPHARM CO., LTD.

www.puriactives.com · service@puripharm.com · +86-572-2745768Building 6, No. 1366 Hongfeng Road, Huzhou, Zhejiang, China

This material is for cosmetic ingredient introduction only and does not constitute pharmaceutical claims; in-vitro and ingredient dossier data are not equivalent to finished-product clinical efficacy; cited third-party literature is for technical reference only. PuriActives® and BioFuco™ are trademarks of PURIPHARM CO., LTD.

PuriActives® MEVAL 100L

Posted on by

SCIENTIFIC MARKETING PRESENTATION · ENGLISH

PuriActives®MEVAL 100L

Mevalonolactone 100LHigh-purity mevalonolactone enabled by synthetic biology

(R)-mevalonolactone · C6H10O3 · MW 130.14

A foundational metabolite of the mevalonate pathway, brought into modern skin and hair science through precision biotechnology.

High purityDefined, controlled composition High activityMevalonate pathway biology
Clean productionControlled biosynthesis Green biotechnologyResource-efficient platform

OPENING PERSPECTIVE

A new generation of metabolic actives is reshaping skin science

Cosmetic science is moving beyond conventional antioxidant and moisturizing concepts toward support for more fundamental biological processes: cellular energy, lipid synthesis, metabolic signaling, epidermal renewal, and barrier homeostasis.

Healthy skin depends not only on structural components, but also on the metabolic pathways that continuously build and maintain them.

Five core processes in metabolic skin scienceCellular energyLipid synthesisMetabolic signalingEpidermal renewalBarrier homeostasis

NARRATIVE MAP

Five questions, one complete storyline

01 Why is the mevalonate pathway essential to skin and hair biology?
02 Why is mevalonolactone scientifically compelling as a cosmetic active?
03 What evidence supports its biological relevance—from cells to human skin?
04 Why do high purity and synthetic-biology production matter to formulators?
05 What new product concepts can be built with PuriActives® MEVAL 100L?

Storyline: Biology (the mevalonate pathway in skin and hair) → Evidence (cells, 3D epidermis, human studies) → Scalp and hair → Platform (synthetic biology and purity) → Applications.

CHAPTER 01 · BIOLOGY

The mevalonate pathway: a central metabolic hub linking lipid synthesis, cellular signaling, and tissue homeostasis

It operates in both the epidermis and the hair follicle.

1.1 Skin care is shifting from surface correction to metabolic support

Healthy skin depends not only on structural components, but also on the metabolic pathways that continuously build and maintain them.

Traditional model Metabolic model
Supply finished materials from the outside:· Occlusive and humectant moisturization· Topical lipid supplementation· Antioxidant quenching· Surface exfoliationThese benefits are real, but often symptomatic and temporary. Support the pathways that generate skin lipids and signals:· De novo lipid biosynthesis· Lipid transport and secretion· Metabolic signaling (PPAR, ABCA12)· Epidermal renewal capacityThis approach targets the underlying mechanism of barrier homeostasis.

Where MEVAL 100L fits: mevalonolactone supplies substrate to the mevalonate pathway—the metabolic route through which every epidermal cell synthesizes cholesterol and isoprenoids.

1.2 Mevalonolactone: a stable, ready-to-use form of a foundational metabolite


ode=”block” data-draft-type=”table” data-size=”normal” data-row-style=”normal”>

(R)-mevalonolactoneLactone form (R)-mevalonateOpen-chain form


aft-node=”block” data-draft-type=”table” data-size=”normal” data-row-style=”normal”>

(R)-mevalonolactoneLactone form (R)-mevalonateOpen-chain form

Reversible hydrolysis in aqueous environments

INCI / CAS Mevalonolactone / 674-26-0 (EC 211-615-0)
Formula / MW C6H10O3 / 130.14
Active configuration (R)-(–)-mevalonolactone, the naturally bioactive enantiomer
Regulatory identity EU CosIng (humectant); China IECIC 2021 (No. 03342)

Why the lactone form?

Mevalonolactone is the intramolecular δ-lactone of mevalonate; the two forms interconvert in water. The lactone is chemically stable and easier to formulate and store. Like a prodrug-like delivery form, it hydrolyzes in the aqueous environment of skin into the biologically active acid.

Isolated hepatocytes take up the lactone and channel it into sterol synthesis at least as efficiently as the free acid.

Sources: Chen B. et al., Skin Res Technol. 2022;28:804–814; Edwards P.A. et al., J Biol Chem. 1983;258:7272–7275; PubMed 901801.

1.3 One pathway supplies the lipids that maintain the barrier

  • HMG-CoA reductase: the rate-limiting step; inhibited by statins.
  • Mevalonate: the first committed product; can be supplied by mevalonolactone.
  • Squalene → cholesterol: a structural lipid of the stratum corneum barrier.
  • Coenzyme Q10: supports mitochondrial electron transport and antioxidant defense.
  • Dolichol: supports protein N-glycosylation in the endoplasmic reticulum.
  • Protein prenylation: anchors Ras/Rho-family signaling GTPases to membranes.

When pathway flux declines with age or stress, the supply of barrier lipids declines as well. Supporting the pathway supports the barrier.

1.4 Ceramides, cholesterol, and free fatty acids form the “mortar” of the barrier

  • Ceramides: the backbone of lamellar sheets.
  • Cholesterol: regulates lamellar fluidity and packing; its synthesis is required for barrier repair.
  • Free fatty acids: complete the crystalline lipid matrix that limits water loss.

Of these three, cholesterol supply depends directly on the mevalonate pathway.

1.5 Blocking the pathway impairs the barrier; adding mevalonate restores it

Condition Observation
ControlVehicle-treated mouse epidermis Normal lamellar body structure; barrier recovery follows the normal time course after disruption.
Pathway inhibitionTopical HMG-CoA reductase inhibitor Abnormal lamellar body morphology; delayed barrier recovery.
Inhibition + mevalonateCo-application of mevalonate or cholesterol Lamellar body structure normalizes and recovery is rescued. Cholesterol produces the same rescue effect.

Epidermal cholesterol synthesis is causally required for barrier repair—and mevalonate supplementation can reverse this deficit.

Source: Feingold et al., J Clin Invest, 1990;86(5):1738–1745. Topical lovastatin model in mouse epidermis.

1.6 Cholesterol synthesis falls in aged epidermis—and mevalonate helps restore it

  • Cholesterol synthesis in aged epidermis falls to about half the young level.
  • Topical cholesterol only partially restores synthesis.
  • Topical mevalonate restores synthesis close to the young level and improves barrier recovery.
  • The effect is age-dependent: young skin is not affected.

Supplying a pathway substrate outperforms supplying the end product.

CHAPTER 02 · EVIDENCE

From cells to skin: lipid synthesis, 3D epidermal models, and a randomized human study

This chapter also includes independent technical literature on fermentation-derived (R)-mevalonolactone.

2.1 Two complementary routes in keratinocytes

  • Route 1 | Substrate supply: supplies the mevalonate pathway downstream of the rate-limiting step, supporting cholesterol, isoprenoid, ceramide, and free fatty acid production.
  • Route 2 | Metabolic signaling: mevalonate-derived signaling increases PPARβ/δ expression (mRNA ~1.7-fold), followed by increased ABCA12 and lamellar bodies, enabling more lipid transport and secretion into the stratum corneum.
  • The effect disappears after PPARβ/δ knockdown by siRNA.

Mechanism established in cultured human keratinocytes: Chen et al., Skin Res Technol, 2022;28(6):804–814.

2.2 In vitro: free fatty acid output increases severalfold


Control — Nile Red staining + MVL — stronger lipid fluorescence

 

Control — Nile Red staining + MVL — stronger lipid fluorescence
  • Free fatty acids are one of the three major structural lipids of the barrier.
  • The largest increases occur in long-chain fatty acids—the same family of raw materials used to build ceramides.
  • Nile Red fluorescence visually confirms the lipid increase in the same model.

This pathway does more than synthesize cholesterol—it amplifies the broader lipid-synthesis program.

Fold changes: Chen et al., Skin Res Technol, 2022. Nile Red images: independent technical literature on fermentation-derived (R)-mevalonolactone, presented at the 132nd Annual Meeting of the Pharmaceutical Society of Japan.

2.3 3D epidermal model: TEWL falls to 27% of control

  • TEWL (transepidermal water loss) is a standard functional measure of barrier integrity.
  • A 73% reduction in a living, stratified epidermal model goes beyond what a single-cell assay can show.
  • The result connects cellular lipid data with tissue-level barrier performance.

From lipid biochemistry to a functional barrier—closed within the same model system.

2.4 Randomized human study: 0.1% MVL emulsion improves barrier and lipids

Sixty-six women in winter; randomized, vehicle-controlled; 0.1% mevalonolactone emulsion applied twice daily for 2 weeks (MVL n=30 and vehicle n=29 included in the analysis).

  • Winter conditions increased TEWL; the MVL group barely increased (+1.17), while the vehicle group increased markedly (+4.91).
  • Surface lipids increased in the MVL group (+3.50) and decreased with vehicle (−2.26), consistent with the in vitro lipid data.
  • Stratum corneum hydration improved significantly versus vehicle (p < 0.01). Together, the three measures indicate a stronger, better-supplied barrier.

The pathway-level mechanism observed in vitro translates into measurable benefits in human skin.

2.5 Independent split-face data: (R)-MVL is associated with visible wrinkle improvement

Independent technical literature on fermentation-derived (R)-mevalonolactone (not a PuriPharm study): randomized split-face trial, 24 women, 0.05% cream, 8 weeks.


Before use After 8 weeks

 

Before use After 8 weeks

Skin surface replicas (crow’s-feet area), SV600 analysis: finer and shallower texture after 8 weeks.

Additional data from the same literature

  • Water retention in a 3D epidermal model was approximately three times the control.
  • TEWL decreased from approximately 4.3 to 1.2 g/m²/h (n=9).

Source: independent technical literature on fermentation-derived (R)-mevalonolactone. Not a PuriPharm study; not measured data for MEVAL 100L.

2.6 Early signals beyond the barrier

Antioxidant network· The mevalonate pathway also builds the isoprenoid side chain of coenzyme Q10.· Patent literature proposes mevalonolactone to support epidermal CoQ10 and antioxidant defense.· Mechanistic rationale only; human data are not yet available. Microbiome and safety· MVL inhibits Staphylococcus epidermidis biofilm formation in vitro.· Relevant to the skin and scalp surface ecosystem.· Oral-intake studies report a favorable safety profile in models.

Directional early signals—development opportunities, not current product claims.

Sources: KR10-2018-0114391 A (melanin/tyrosinase); DE10148266 A1 (CoQ10 concept); Scopel et al., 2014, PMID 24111986; Yogev et al., PNAS, 2023;120(7):e2217831120.

2.7 Summary: one molecule, a five-step chain

Step Link Meaning
01 Pathway supply Mevalonate energizes lipid-synthesis pathways
02 Lipid output ↑ Cholesterol, free fatty acids, ceramide precursors
03 Barrier function ↑ TEWL falls in 3D epidermis and human skin
04 Hydration and lipids ↑ Human RCT: hydration and surface lipids increase
05 Firmness and texture Literature: improved elasticity and wrinkle appearance

Healthy aging means keeping the skin’s own production line running.MEVAL 100L supports the source—not just the surface.

CHAPTER 03 · SCALP AND HAIR

The same pathway: hair follicles and epidermis share a lipid supply line

The hair follicle is one of the most metabolically active structures in the human body.

3.1 Hair follicles and epidermis rely on the same cholesterol supply

What the literature shows

  • The follicular cholesterol-synthesis machinery is highly active. DHCR24, the terminal enzyme of cholesterol synthesis, is strongly expressed in hair follicles, and cholesterol is incorporated into the hair shaft during hair formation.
  • The pathway is downregulated in hair loss. HMGCR and HMGCS1—genes controlling mevalonate production—are downregulated in patients with alopecia.
  • Disrupting lipid signaling damages follicles. PPARγ deletion causes scarring alopecia in animal models.
  • Recent research links cholesterol to hair growth. A 2025 report connects cholesterol with sympathetic-nerve activation, hair-follicle stem-cell proliferation, and hair loss when synthesis is blocked.
ImplicationCholesterol supply in the follicle is active and essential—and compromised in hair loss. Rational entry pointA pathway-supporting active can supply the substrate used by the tissue’s own lipid-building machinery.

Sources: Palmer et al., 2020; Karnik et al., 2009; Nikhila et al., 2025; Guo et al., 2025. Follicle data are literature evidence, not measured results for MEVAL 100L.

3.2 Scalp care is becoming “skinified”—and the follicle is a metabolic organ

The scalp is skin· The scalp stratum corneum uses the same lipid triad: ceramides, cholesterol, and free fatty acids.· Barrier damage appears as dryness, tightness, and flaking—the most common scalp-care concerns.· A healthy scalp barrier is the foundation for all hair benefits. The follicle is a metabolic organ· Anagen follicles are among the most metabolically active tissues in the body.· Hair-shaft construction depends on cholesterol synthesis and lipid supply.· Pathway genes are downregulated in hair loss—supply matters.

MEVAL 100L uses one pathway for two targets: the scalp barrier above and follicle metabolism below.

CHAPTER 04 · PURIPHARM PLATFORM

Synthetic biology turns pathway insight into a manufacturable active

High purity, the correct enantiomer, clean production, and scalability.

4.1 Producing mevalonolactone in a nature-inspired way

Traditional chemical route PuriPharm route — fermentation
· Petrochemical feedstocks· Multi-step synthesis relying on protecting-group chemistry· Racemic product—50% (R), 50% inactive (S)· Solvent-intensive purification· Process waste at every step · Renewable feedstocks—sugars rather than petrochemicals· Engineered microorganisms run the full pathway in a single fermenter· Stereoselective—the biologically active (R)-enantiomer· Mild aqueous conditions—ambient temperature and pressure· Scalable—reported titers above 100 g/L in the literature

Literature and patent data; not specifications for MEVAL 100L.

4.2 Three disciplines, one value chain

01 Biology identifies the pathway.
02 Biotechnology manufactures the active.
03 Cosmetic science turns it into benefits.

This is the PuriPharm development model behind MEVAL 100L.

4.3 Only the (R)-enantiomer enters the pathway

  • Mevalonolactone has one stereocenter; the (R)-form is the natural form used by mevalonate kinase.
  • The (S)-form does not enter the pathway.
  • Half of a racemic mixture is an inactive “passenger.” Enantioselective fermentation removes it—every gram of MEVAL 100L is in the form skin can use.

4.4 Precision biology, cleaner chemistry

  • Renewable feedstocks: sugars replace petrochemical starting materials.
  • Mild aqueous fermentation: ambient temperature and pressure, without harsh reagents.
  • Fewer steps, less waste: one fermenter replaces a multi-step synthesis sequence.
  • A molecule biology already knows: the lactone hydrolyzes to mevalonate, a natural human metabolite.

Qualitative process attributes only; no quantitative sustainability claim is made. Life-cycle data are available upon request.

CHAPTER 05 · PRODUCT AND APPLICATIONS

MEVAL 100L: a clearly characterized molecule with nothing to hide

5.1 Product identity and recommended use level

INCI name Mevalonolactone
CAS / EC No. 674-26-0 / 211-615-0
Formula C6H10O3 · MW 130.14 g/mol · water-miscible lactone
Stereochemistry (R)-enantiomer—the bioactive form, produced by fermentation
CosIng function Humectant (EU CosIng database)
IECIC 2021 (China) Listed, No. 03342—historical maximum leave-on use level 0.05%
Recommended use 0.05–1%—based on published in vitro and human studies

Only publicly verifiable identity information is listed here; no specifications are invented. Full product specifications (appearance, purity, enantiomeric excess, microbial limits) are available from PuriPharm Co., Ltd.

5.2 One active, six skin-care directions (ranked by evidence strength)

Direction Evidence Product relevance
01 Barrier repair Human RCT Daily moisturizing and barrier creams. Supplies substrate for all three barrier lipids; TEWL benefits are validated in 3D epidermis and human skin.
02 Healthy aging and firming Technical literature Elasticity and wrinkle-appearance care. Independent split-face data for (R)-MVL show measurable improvement within 8 weeks.
03 Dry and sensitive skin Human RCT Winter protection and recovery. In the randomized study, hydration increased and surface lipids were preserved under winter stress.
04 Tone and radiance Exploratory Patent data show inhibition of melanin and tyrosinase in B-16 melanocytes. A development direction, not a claim.
05 Antioxidant support Exploratory The same pathway builds the side chain of coenzyme Q10, providing a mechanistic basis for pairing with antioxidant systems.
06 Microbiome-friendly care Exploratory In vitro inhibition of S. epidermidis biofilm suggests relevance to the surface ecosystem. Early signal only.

Directions 04–06 are supported only by patent-level or in vitro data; they represent development potential, not finished-product claims.

5.3 Scalp and hair: four entry points, one logic

01 Scalp barrier care｜Skin evidence directly applicableLeave-on scalp tonics and serums for dry, tight, flaky scalps. The scalp stratum corneum uses the same lipid triad as facial skin—barrier evidence can be transferred directly.
02 Hair-growth support concept｜ExploratoryThe follicular cholesterol machinery is active during anagen and downregulated in hair loss. Supplying pathway substrate is a rational—but still to be validated—growth-support strategy.
03 Aging-scalp care｜Analogy to skin agingScalp skin ages like facial skin: lipid synthesis declines and the barrier weakens. The healthy-aging logic from Chapter 2 naturally extends to the scalp.
04 Microbiome-friendly scalp care｜ExploratoryIn vitro biofilm inhibition points toward scalp-ecosystem applications—an early signal to be developed, not a claim.

Follicle-level evidence comes from pathway literature; product-level hair claims require dedicated studies. PuriPharm welcomes co-development projects.

5.4 Three skin-care concepts to start the co-development conversation

Concept A · Face | Metabolic barrier serum

0.1% MEVAL 100L combined with a ceramide–cholesterol–free fatty acid complex. Substrate plus building blocks: the serum replenishes finished lipids while feeding lipid synthesis.

Evidence anchor—human RCT: TEWL remained at +1.17 versus +4.91 with vehicle; hydration and surface lipids increased.

Concept B · Face/body | Winter repair cream

0.05–0.1% MEVAL 100L in a rich physiological-lipid base. Designed for seasonal barrier stress: dryness, tightness, and elevated TEWL in cold weather.

Evidence anchor—the randomized study was conducted in winter under real barrier stress.

Concept C · Face | Firming serum

0.05% MEVAL 100L paired with a peptide system. A metabolic view of firming: lipid supply improves skin quality while peptide signaling acts on the dermal matrix.

Evidence anchor—technical literature: elasticity R3 improved within 8 weeks (0.05% cream).

Concepts are illustrative starting points for co-development. Final claims must be validated in the finished formula; technical-literature anchors do not constitute measured data for MEVAL 100L.

5.5 Three scalp and hair concepts on the same platform

Concept A · Leave-on scalp | Scalp barrier tonic

0.05–0.1% MEVAL 100L in a lightweight water-based scalp tonic. Addresses dryness, tightness, and flaking at the source—the scalp’s own lipid supply.

Logic anchor—scalp barrier biology matches facial skin; skin RCT evidence can be transferred directly.

Concept B · Scalp serum | Anagen-support serum

0.1% MEVAL 100L in a follicle-directed leave-on serum. A metabolic concept for hair-density care: support the pathway on which anagen follicles depend.

Logic anchor—pathway genes are downregulated in hair loss (literature). Product-level validation is required.

Concept C · Scalp essence | Aging-scalp essence

0.05–0.1% MEVAL 100L paired with antioxidant ingredients. Extends the healthy-aging story to the scalp: lipid supply, barrier quality, and comfort.

Logic anchor—cholesterol data in aged skin (Haratake 2000) are relevant to scalp-skin aging.

Concepts are illustrative starting points for co-development. Hair-growth positioning is exploratory and requires dedicated product-level studies before any claim is made.

5.6 Formulating with MEVAL 100L: simple, compatible, literature-guided

Practical guidance Pairing logic
· Use level: 0.05–1%. Human data are concentrated at 0.05–0.1%; observe local limits (China IECIC: historical maximum leave-on use level 0.05%).· Water-miscible lactone. Can be added directly to aqueous systems and the water phase of emulsions.· Lactone ⇌ acid equilibrium. In water, MVL equilibrates with mevalonate—both are pathway-relevant; conventional skin-care pH is suitable.· Small, stable molecule. MW 130.14—no macromolecular handling constraints.· Compatible with physiological lipids. Designed to pair with ceramides, cholesterol, and fatty acids. + Physiological lipidsSubstrate + building blocks—a complete barrier concept+ HumectantsBarrier lipid supply + water retention—a moisturization concept+ Peptides / antioxidantsMetabolic support + signaling actives—a firming concept

General literature-guided recommendations, not a validated formula. PuriPharm technical service can provide starting formulations and stability support upon request.

CHAPTER 06 · COMMERCIAL VALUE

From science to market: the four-dimensional value framework of MEVAL 100L

01 DifferentiationA new mechanism story—metabolic support for the skin’s own lipid production, not another moisturizer or occlusive.
02 EvidenceA layered evidence package: human RCT, 3D epidermis, and keratinocyte mechanism—plus clearly labeled independent literature.
03 SupplyA fermentation platform: renewable feedstocks, (R)-selectivity, and scalability—consistent quality from batch to batch.
04 ComplianceEstablished INCI identity, CosIng function, and IECIC 2021 listing—a well-documented ingredient.

A differentiated story the marketing team can tell,and an evidence chain the regulatory team can defend.

Four market currents converge in one molecule

Barrier-first skin care Consumers increasingly see barrier health as the foundation of skin quality. MEVAL 100L goes directly to barrier biology—and is supported by human data.
Skin longevity and healthy aging The category is shifting from anti-aging correction toward maintaining the skin’s own production capacity—exactly the metabolic story of the mevalonate pathway.
Skinification of scalp care Scalp products increasingly borrow skin-care actives and language. MEVAL 100L brings scalp-relevant barrier and follicle logic.
Green biotech actives Brands are replacing petrochemical synthesis with fermentation. MEVAL 100L is made by synthetic biology: renewable feedstocks, (R)-selectivity, and clean production.

Positioning MEVAL 100L means standing at the intersection of these four currents.

Qualitative trend mapping only—no market-statistics claim is included.

Why MEVAL 100L: five reasons, one molecule

  1. A real mechanism—the mevalonate pathway is causally required for barrier repair.
  2. Human evidence—a randomized, vehicle-controlled study on real winter-stressed skin.
  3. The correct enantiomer—(R)-selective fermentation rather than a racemic compromise.
  4. Clean and scalable—synthetic-biology production based on renewable feedstocks.
  5. A dual platform—one active spanning skin care and scalp/hair care.

High purity · High activity · Clean production · Green biotechnology

REFERENCES AND DATA SOURCES

  1. Chen B, Lu N, Lee KS, Ye L, Hasegawa C, Maeda K. Application of mevalonolactone prevents deterioration of epidermal barrier function by accelerating the lamellar granule lipid transport system. Skin Res Technol. 2022;28(6):804–814. doi:10.1111/srt.13202.
  2. Feingold KR, Man MQ, Menon GK, Cho SS, Brown BE, Elias PM. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest. 1990;86(5):1738–1745.
  3. Haratake A, Ikenaga K, Katoh N, Uchiwa H, Hirano S, Yasuno H. Topical mevalonic acid stimulates de novo cholesterol synthesis and epidermal permeability barrier homeostasis in aged mice. J Invest Dermatol. 2000;114(2):247–252. doi:10.1046/j.1523-1747.2000.00875.x.
  4. Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta. 2014;1841(3):280–294. doi:10.1016/j.bbalip.2013.11.007.
  5. Edwards PA, Lan SF, Tanaka RD, Fogelman AM. Mevalonolactone inhibits the rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat hepatocytes. J Biol Chem. 1983;258(12):7272–7275.
  6. Scopel M, Abraham WR, Antunes AL, Henriques AT, Macedo AJ. Mevalonolactone: an inhibitor of Staphylococcus epidermidis adherence and biofilm formation. Med Chem. 2014;10(3):246–251. doi:10.2174/15734064113096660055.
  7. Yogev Y, Shorer Z, Koifman A, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci USA. 2023;120(7):e2217831120. doi:10.1073/pnas.2217831120.
  8. Palmer MA, Blakeborough L, Harries M, Haslam IS. Cholesterol homeostasis: links to hair follicle biology and hair disorders. Exp Dermatol. 2020;29(4):299–311. doi:10.1111/exd.13993.
  9. Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, Mirmirani P. Hair follicle stem cell-specific PPARγ deletion causes scarring alopecia. J Invest Dermatol. 2009;129(5):1243–1257.
  10. Panicker SP, Ganguly T, Consolo M, Price V, Mirmirani P, Honda K, Karnik P. Sterol intermediates of cholesterol biosynthesis inhibit hair growth and trigger an innate immune response in cicatricial alopecia. PLoS One. 2012;7(6):e38449. doi:10.1371/journal.pone.0038449.
  11. Nikhila L, Surya S, Najeeb SH, et al. Disrupted cholesterol biosynthesis and hair follicle stem cell impairment in the onset of alopecia. PLoS One. 2025;20(9):e0308455. doi:10.1371/journal.pone.0308455.
  12. Guo M, Jiang J, Zhang A, Yu W, Huang X. Cholesterol promotes hair growth through activating sympathetic nerves and enhancing the proliferation of hair follicle stem cells. Mol Med. 2025;31(1):86. doi:10.1186/s10020-025-01139-z.
  13. Yamashita M, et al. Mevalonolactone fermentation by Saccharomycopsis fibuligera. Fragrance Journal. 2000;28(2):62–65.
  14. Korean patent application KR10-2018-0114391 A (skin-brightening use of mevalonolactone); Korean patent KR101625898 B1 (fermentative production); German patent application DE10148266 A1 (CoQ10 support); international application WO2021041363 A1 (lipidomic effects).
  15. Independent technical literature on fermentation-derived (R)-mevalonolactone: split-face elasticity study (0.05% cream, 8 weeks, n=24) and Nile Red lipid data, 132nd Annual Meeting of the Pharmaceutical Society of Japan.

Data labeled as “technical literature” in this presentation were generated with fermentation-derived (R)-mevalonolactone—not MEVAL 100L—and are shown only as literature evidence.

Let’s build the next generation ofmetabolic actives together.

PuriPharm Co., Ltd.Building 6, No. 1366 Hongfeng Road, Huzhou, Zhejiang, China+86 572 2745768 · www.puriactives.com

PuriActives® MEVAL Mevalonolactone 100L — Product Presentation

NanoActive™ r-Retinoate

Posted on by

NanoActive™ r-Retinoate

A new-generation, high-performance vitamin A active

8×RETINOL POWERHigh efficacy at low concentration · High stability · Potential for high tolerabilityA new-generation hybrid retinoid INCI Retinyl Retinoate

PuriPharm Co. Ltd.

Source：Structure: PubChem CID 10303376. The 8× claim refers only to the low-concentration in vitro collagen synthesis experiment detailed in “8× Retinol-Level Collagen Performance.”

01 MOLECULAR DESIGN

The traditional vitamin A trade-off

Traditional vitamin A actives rarely combine activity, stability, and tolerability

Retinoid Core attribute Key limitation
Retinoic Acid High activity Higher irritation potential and greater restrictions on use
Retinol Gold standard Sensitive to light, heat, oxygen, and other factors
Retinyl Esters High stability Usually lower biological activity

High activity + High stability + High tolerability

What if one vitamin A molecule could offer all three?

Next: the hybrid retinoid architecture

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005.

01 MOLECULAR DESIGN

Hybrid Retinoid molecular architecture

One molecule combines the structural logic of two classic retinoids

RETINOL + RETINOIC ACID

Esterification forms RETINYL RETINOATE

No. Design logic
01 Block the Retinoic Acid carboxyl group
02 Preserve the key retinoid ring structure and polyene chain
03 Rebalance activity, stability, and tolerability

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005. Structure: PubChem CID 10303376.

01 MOLECULAR DESIGN

NanoActive™ r-Retinoate · Product overview

Core molecular information and market positioning

Item Information
Product NanoActive™ r-Retinoate
INCI name Retinyl Retinoate
Category Hybrid RetinoidVitamin A derivativeAnti-aging active
Molecular data Formula C₄₀H₅₆O₂Molecular weight 568.87CAS 15498-86-9
Absorption maximum λmax 333 nm; Retinol 323 nm

8× Retinol collagen performancePhotostable retinoidImproved thermal stabilityDirect retinoid bioactivityHyaluronan boostHigh efficacy at low concentrationSkin and scalp applicationsCompatible with nano-delivery

Source：PubChem CID 10303376; Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005. Appearance, active content, particle size, PDI, carrier composition, recommended use level, pH, addition temperature, and storage conditions must follow the latest PuriPharm TDS / SPEC / COA.

02 COLLAGEN PERFORMANCE

8× Retinol-level collagen performance

Approximately eight times the collagen synthesis response of Retinol at low concentration

8×Collagen biosynthesis at low concentration41.29% ÷ 4.94% ≈ 8.36× Retinol+4.94%Retinyl Retinoate+41.29%

Test concentration: 10⁻⁶% (w/v)

Lower concentration, more collagen

Source：*In an in vitro collagen synthesis experiment at 10⁻⁶% (w/v), Retinyl Retinoate increased collagen synthesis by 41.29%, versus 4.94% with Retinol, equivalent to approximately 8.36×. US7173062B2, “Method for the Improvement of Skin Wrinkles Using Retinyl Retinoate.” See also Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005.

02 COLLAGEN PERFORMANCE

Lower concentration, more collagen

Retinyl Retinoate shows strong collagen synthesis performance even at low concentrations

Concentration Retinoic Acid Retinol Retinyl Palmitate Retinyl Retinoate
0.1 μM 1% — — 1.5%
1 μM 14% 10% 2% 14%
10 μM 52% 42% 14% 48%

High efficacy at low concentration

Outperforms Retinol in the low-concentration range and approaches Retinoic Acid at some concentrations

Metric: increase in collagen synthesis (%)

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005. Redrawn from Figure 6. Bar values are visual readings from the axes and preserve the trend reported in the article.

02 COLLAGEN PERFORMANCE

A retinoid with direct biological activity

The molecule can display retinoid activity without first undergoing complete hydrolysis

Route Sequence Interpretation
Traditional Retinyl Ester Retinyl Ester → Retinol → Retinal → Retinoic Acid → RAR Requires multiple conversion steps before entering RAR signaling
Retinyl Retinoate Retinyl Retinoate → observed biological effect Direct retinoid activity

HPLC evidence

After two days of incubation with normal human skin fibroblasts, HPLC detected no new peaks corresponding to Retinol or Retinoic Acid.

The authors therefore attributed the observed biological activity to the molecule itself rather than simple hydrolysis.

Not an ordinary retinyl ester

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005.

02 COLLAGEN PERFORMANCE

Promotes synthesis and limits degradation

Bidirectional collagen management through RAR, AP-1, and collagen signaling

Photoaging cascade Direction associated with NanoActive™ r-Retinoate
UV / environmental stress → c-Jun / AP-1 ↑ → collagenase / MMP ↑ → collagen degradation → wrinkles Retinoid signaling / RAR → AP-1 / c-Jun ↓
Collagen degradation Promotes synthesis: Collagen Biosynthesis ↑
Increased collagenase / MMP Reduces degradation signals: Collagenase / MMP ↓

52%

Collagenase inhibition

Retinyl Retinoate > Retinol

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005. With RARα expression, collagenase expression was inhibited by approximately 33% with Retinol, 52% with Retinyl Retinoate, and 64% with Retinoic Acid; also supported by US7173062B2, “Method for the Improvement of Skin Wrinkles Using Retinyl Retinoate.”

03 STABILITY & TOLERABILITY

Designed for photostability

Retinoid performance that withstands light exposure

48 h

UVA photostability

The main structure retained markedly greater stability even after 48 hours of UVA exposure.

UVA: 356 nm; observations at 2, 12, 24, and 48 hours

Compound 0 h 2 h 12 h 24 h 48 h
Retinyl Retinoate Baseline Stable Stable Stable Only minor noise / no qualitative change
Retinol Baseline Clear degradation No longer reliably identified qualitatively No longer reliably identified qualitatively No longer reliably identified qualitatively

λmax: Retinol 323 nm; Retinyl Retinoate 333 nm

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005.; US7173062B2, “Method for the Improvement of Skin Wrinkles Using Retinyl Retinoate.” Photostability experiment: UVA 356 nm and qualitative ¹H NMR. “48 h” is the study duration, not a direct quantitative claim of percentage remaining.

03 STABILITY & TOLERABILITY

Stability beyond light exposure

Thermal stability was clearly better than Retinol after four weeks under accelerated conditions

Four-week condition Retinol remaining Retinyl Retinoate remaining
Room temperature 52.23% 89.21%
40°C 34.51% 68.23%
4°C 95.52% 99.65%

Improved thermal stabilityMore robust formulationsMore reliable retinoid performance

Source：US7173062B2, “Method for the Improvement of Skin Wrinkles Using Retinyl Retinoate.” Thermal stability experiment: HPLC quantification after four weeks at room temperature, 40°C, and 4°C.

03 STABILITY & TOLERABILITY

High performance with greater mildness

A wider cellular tolerance window and evidence from a human occlusive patch test

In vitro MTT IC₅₀
+60%IC₅₀ versus RetinolLower cytotoxicity in this in vitro model In vitro MTTIC₅₀Retinol25 μMRetinyl Retinoate40 μM
24 h human occlusive patch test Concentration Irritation index; lower is better
Retinol 0.075% 2.5
r-Retinoate 0.075% 1.3
r-Retinoate 0.30% 1.3
r-Retinoate 0.55% 1.3

High performance and low irritation in the same profile

Source：Kim H, Kim B, Kim H, et al. “Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.” Bioorganic & Medicinal Chemistry. 2008;16(12):6387–6393. DOI: 10.1016/j.bmc.2008.05.005. Normal human skin fibroblast MTT assay: IC₅₀ 40 μM versus 25 μM for Retinol. Human occlusive patch data: US7173062B2, “Method for the Improvement of Skin Wrinkles Using Retinyl Retinoate.”

04 BEYOND COLLAGEN

7.8× hyaluronan production

Extending from wrinkle care to hydration, plumpness, and barrier support

7.8×

Hyaluronan production

Primary human keratinocytes; 1 μM / 24 hRetinaldehyde ≈ 7.6× control

Mechanistic path Outcome
Retinyl Retinoate → HAS2 ↑ Hyaluronan ↑
Hyaluronan ↑ → CD44 interaction Hydration · ECM support · Homeostasis

Retinyl Retinoate upregulated HAS2 and increased CD44-related expression.

Source：Kim JE, Kim B, Kim H, et al. “Retinyl retinoate induces hyaluronan production and less irritation than other retinoids.” Journal of Dermatology. 2010;37(5):448–454. DOI: 10.1111/j.1346-8138.2010.00808.x. In primary human keratinocytes, Retinyl Retinoate at 1 μM for 24 h induced hyaluronan production to approximately 7.8 times the control level.

04 BEYOND COLLAGEN

High activity with less barrier disruption

Lower TEWL impact at the same 0.05% concentration

Retinoid Relative TEWL / barrier disruption ranking
Retinyl Retinoate Lowest
Retinol Low
Retinoic Acid High
Retinaldehyde High

7.8× hyaluronan production + lower TEWL disruption

A better balance of efficacy and tolerability

Source：Kim JE, Kim B, Kim H, et al. “Retinyl retinoate induces hyaluronan production and less irritation than other retinoids.” Journal of Dermatology. 2010;37(5):448–454. DOI: 10.1111/j.1346-8138.2010.00808.x. Hairless-mouse TEWL model with 0.05% comparative application. The ranking redraws the irritation order reported in the article.

05 CLINICAL EVIDENCE

Human evidence with a Retinol comparator

Uncommon direct human comparison against Retinol

0.06%Retinyl RetinoateSignificantly better than 0.075% Retinol 46Korean women · Periorbital wrinklesTwo randomized clinical studies
Study Duration and completers Intervention Frequency
Study 1 12 weeks; 24 completed 0.06% Retinyl Retinoate versus placebo Twice daily
Study 2 8 weeks; 22 completed 0.06% Retinyl Retinoate versus 0.075% Retinol Twice daily

Assessments: global photoaging score · photographs · skin replicas · Visiometer

Wrinkles improved significantly with Retinyl Retinoate versus placebo and Retinol.

Source：Kim H, Kim N, Jung S, et al. “Improvement in skin wrinkles from the use of photostable retinyl retinoate: a randomized controlled trial.” British Journal of Dermatology. 2010;162(3):497–502. DOI: 10.1111/j.1365-2133.2009.09483.x. Skin-replica analysis showed significant improvement, particularly in mean roughness.

05 CLINICAL EVIDENCE

22% greater improvement in maximum roughness

A 12-week double-blind randomized comparison versus 0.075% Retinol

Study design Information
+22%R2 maximum roughnessImprovement rate versus Retinol Study designInformationDesignProspective · Double-blind · Randomized · ControlledParticipants11 Korean women; 35–56 yearsDuration / frequency12 weeks; twice dailyComparison0.06% Retinyl Retinoate versus 0.075% RetinolAnalysisVisiometer R2; 12-week head-to-head comparison

Validated dimensions: fine-line reduction, elasticity, visual wrinkle grade, skin roughness, and dermal distance / intensity.

Source：Kim H, Koh J, Baek J, et al. “Retinyl retinoate, a novel hybrid vitamin derivative, improves photoaged skin: a double-blind, randomized-controlled trial.” Skin Research and Technology. 2011;17(3):380–385. DOI: 10.1111/j.1600-0846.2011.00512.x. At 12 weeks, the improvement rates for visual wrinkles and R2 maximum roughness were 22% higher than with Retinol.

05 CLINICAL EVIDENCE

Beyond anti-aging

Retinoid science for blemish-prone and oily skin

Protocol: 0.05% Retinyl Retinoate · 8 weeks · double-blind · vehicle-controlled · split-face; 15 women with mild-to-moderate acne.

Eight-week outcome Vehicle Retinyl Retinoate
Total lesion count −26.47% −38.58%
Inflammatory lesions −35.14% −43.62%
Non-inflammatory lesions −19.79% −33.98%

−27.18%

Forehead sebum

Baseline 104.86 μg/cm²; week 8: 76.36 μg/cm²

Blemish-prone skin careSebum balanceFollicular keratinization careClearer-looking skin

Source：Kim B, et al. “Retinyl Retinoate, a Retinoid Derivative Improves Acne Vulgaris in Double-blind, Vehicle-controlled Clinical Study.” Tissue Engineering and Regenerative Medicine. 2013;10(5):260–265. DOI: 10.1007/s13770-012-1088-z. Percentages are reductions in lesion counts after eight weeks; the change in sebum was statistically significant.

06 DELIVERY PLATFORM

Molecule × nano-delivery

Unlocking the full potential of r-Retinoate

Retinyl Retinoate is highly lipophilic, so formulation must solve several engineering challenges:

01 Dispersibility02 Stability03 Drug loading04 Skin delivery05 Controlled release

RETINYL RETINOATE + Nano-delivery

A performance-optimized retinoid delivery system

Published NLC feasibility evidence Value
Particle size 230–300 nm
PDI No value listed in the source slide
PRECIROL-NLC encapsulation efficiency 97.8%
COMPRITOL-NLC encapsulation efficiency 93.8%

These values describe a published NLC system and are not specifications for NanoActive™ r-Retinoate.

Source：Lee SG, Jeong JH, Kim SR, et al. “Topical formulation of retinyl retinoate employing nanostructured lipid carriers.” Journal of Pharmaceutical Investigation. 2012;42(5):243–250. DOI: 10.1007/s40005-012-0036-1. Particle size, PDI, encapsulation efficiency, and carrier parameters for NanoActive™ itself must follow authentic PuriPharm TDS / SPEC / COA documents.

06 DELIVERY PLATFORM

Encapsulation amplifies delivery performance

Independent research shows that advanced delivery can further enhance Retinyl Retinoate

Form Exposure / penetration Delivery performance
Free RR Conventional exposure; limited penetration —
Encapsulated RR Improved penetration More efficient delivery; enhanced anti-wrinkle performance

Encapsulation → Improved penetration → More efficient delivery → Enhanced anti-wrinkle performance

+6.05%Visual wrinkle improvement +8.03%R2 maximum roughness

Source：Kim H, et al. “Novel anti-wrinkle effect of cosmeceutical product with new retinyl retinoate microsphere using biodegradable polymer.” Skin Research and Technology. 2012;18(1):70–76. DOI: 10.1111/j.1600-0846.2011.00533.x. Outcomes compare a 3% PLA–retinyl retinoate (2%) microsphere cream with a 0.06% Retinyl Retinoate cream over four weeks. Published PLA microsphere evidence does not represent NanoActive™ technology.

07 APPLICATIONS

From face to scalp

Advanced retinoid science for scalp care

SkinWrinkle careCollagen renewalHyaluronan boostFirmingRefined texturePhotoaging careBlemish-prone skinSebum balance ScalpScalp renewalSebum balanceFollicular keratinization careScalp anti-agingPilosebaceous unit careHealthy follicular environment

Retinoid signaling is present in hair follicles, sebaceous glands, and interfollicular epidermis, and participates in epithelial differentiation, sebaceous biology, and follicular keratinization.

Source：Mechanistic background: Everts HB, Sundberg JP, King LE Jr, Ong DE. “Immunolocalization of enzymes, binding proteins, and receptors sufficient for retinoic acid synthesis and signaling during the hair cycle.” Journal of Investigative Dermatology. 2007;127(7):1593–1604. DOI: 10.1038/sj.jid.5700753. Scalp positioning covers scalp health, anti-aging, oil control, and support for the follicular environment. No direct hair-growth claim should be made without product-specific clinical evidence.

07 APPLICATIONS

One retinoid, multiple performance dimensions

Eight efficacy dimensions create a complete premium active platform

No. Performance dimension
01 8× Collagen Performance
02 Wrinkle Reduction
03 Photostability
04 Thermal Stability
05 Hyaluronan Boost
06 Better Tolerance
07 Blemish & Sebum Care
08 Scalp Renewal

Source：The efficacy dimensions summarize the preceding evidence. Each quantitative claim retains its experimental model, comparator, concentration, and source in the corresponding section.

07 APPLICATIONS

Designed for the next generation of beauty innovation

Premium dual applications across skin and scalp

Skin carePremium anti-aging serumLine-smoothing serumEye serum / eye creamNight repairDay-and-night retinoid productsPhotoaging careFirming and elasticity productsHydrating anti-aging productsBlemish-prone skin careOily-skin serum Scalp and hair careScalp anti-aging essenceScalp anti-aging serumScalp renewal serumOily-scalp serumFollicular environment careLeave-on scalp carePremium scalp ampoule

Formats: serum · cream · lotion · ampoule · eye care · scalp serum · leave-on care

Source：Application guidance is conceptual and based on published Retinyl Retinoate evidence. Recommended use level, pH, addition temperature, solubility, compatibility, storage conditions, and finished-product stability for NanoActive™ r-Retinoate must follow official PuriPharm TDS / SPEC / COA documents. No product-specific parameters are inferred here.

CLOSING

NanoActive™ r-Retinoate

Higher performance at a lower concentration. Redefining next-generation vitamin A anti-aging technology.

8× collagen performancePhotostabilityClinically evaluatedHyaluronan boostNano-delivery

A new-generation, high-performance vitamin A active

PuriPharm Co. Ltd.

Source：*“8× Retinol Power” is a marketing shorthand for an approximately 8.36-fold difference in low-concentration in vitro collagen synthesis performance: 41.29% versus 4.94% at 10⁻⁶% w/v. Source: US7173062B2. It does not mean 8× RAR activation, 8× human wrinkle reduction, 8× lower irritation, or 8× performance across all biological endpoints.

PuriActives®SupraSalix A Supramolecular Salicylic Acid System for Clearer,Calmer and Better-Balanced Skin

Posted on by

THE NEW STANDARD IN CLARIFYING CARE

THE SALICYLIC ACID PARADOX

BEYOND CONVENTIONAL FREE SALICYLIC ACID

INTRODUCING PURIACTIVES® SUPRASALIX

WHAT “SUPRAMOLECULAR” MEANS

FOUR COMPONENTS, ONE INTEGRATED SYSTEM

SALICYLIC ACID: PRECISION CLARIFICATION

ZINC GLYCINATE: ANTIOXIDANT & COMFORT

XYLOGLUCAN: A SOFT PROTECTIVE INTERFACE

ALPHA-GLUCAN OLIGOSACCHARIDE: MICROBIOME CARE

THE 4D SUPRASALIX PLATFORM

A MULTI-LEVEL SKIN-BALANCE STRATEGY

DESIGNED FOR BETTER FORMULATION FREEDOM

EVIDENCE ARCHITECTURE

PUBLISHED SALICYLIC ACID EVIDENCE: CONTEXT

PUBLISHED ZINC-GLYCINE EVIDENCE

FROM FACIAL CLARITY TO SCALP BALANCE

FORMULATION FORMATS

PRODUCT-SPECIFIC VALIDATION ROADMAP

RESPONSIBLE CLAIMS & REGULATORY AWARENESS

WHY PURIACTIVES® SUPRASALIX

NanoActive®Curcumin

Posted on by

Market Background

Why Curcumin?

Conventional Curcumin Challenges

NanoActive® Nano-Delivery Platform

Product Concept

Core Benefits

Mechanism 1: Antioxidant Defense

Mechanism 2: Soothing & Skin Comfort

Mechanism 3: Photoaging Care

Mechanism 4: Skin Radiance & Even Tone

Nano-Encapsulation Advantages

Formulation Applications

Formulation Guidelines

Suggested Product Claims

Comparison with Common Antioxidants

Target Formulation Concepts

The PuriPharm Advantage

Safety & Compliance

Marketing Copy Suggestions

Scientific References

Product Data Sheet: NanoActive® Bakuchiol

Posted on by

1. Product Description

NanoActive® Bakuchiol is a premium, biomimetic active ingredient concept featuring highly concentrated Bakuchiol encapsulated within a proprietary sub-micron lipid nanocarrier system. Derived from the seeds of Psoralea corylifolia, this retinol-like botanical active is engineered for enhanced stability, superior aqueous dispersion, and high tolerability in modern anti-aging, sensitive-skin, and blemish-care applications.

2. INCI Name & Composition

  • INCI Name: Water (Aqua), Glycerin, Bakuchiol, Phospholipids, Caprylic/Capric Triglyceride.
  • Source: 100% Plant-derived active (Bakuchiol).
  • Solubility: Highly miscible in water-based phases; easily incorporated into aqueous serums, hydrogels, and O/W emulsions.

3. Chemical-Physical & Microbiological Specifications

Designed to meet stringent global quality standards, ensuring optimal safety and formulation elegance.

4. Key Technical Advantages

  • Retinol-like Efficacy: Acts on the same biological pathways as retinol (e.g., retinoic acid receptor signaling) without the associated irritation or light sensitivity.
  • Aqueous Transparency: The glycerin-water nanocarrier base allows the formulation of crystal-clear serums without the need for harsh solubilizers.
  • Advanced Nano-Delivery: NanoActive® encapsulation ensures controlled, sustained delivery of the 10% active payload deep into the epidermal layers.
  • Skin Barrier Support: Integrated phospholipid bilayer mimics skin lipids, reinforcing the barrier function while delivering the active.

5. Clinical Evidence Highlights

  • Anti-Aging: Supports significant reduction in the appearance of fine lines and wrinkles.
  • Firmness & Elasticity: Promotes the appearance of a firmer skin texture by supporting collagen I, III, and IV expression.
  • Soothing & Inflammation: Effectively supports the reduction of visible redness and inflammation in sensitive and acne-prone skin.
  • Pigmentation: Helps achieve a more uniform skin tone and brightness through the modulation of pigment-related pathways.

6. Formulation Guidelines

  • Recommended Use Level: 1.0% – 5.0% (delivering 0.1% – 0.5% pure Bakuchiol to the final product).
  • Processing:
  • Phase: Add into the water phase or during the final cool-down phase (below 45°C) to maintain the integrity of the nanocarrier system.
  • pH Stability: Optimal range 4.5 – 7.0.
  • Antioxidant Protection: Since the delivery system relies on an aqueous/glycerin base, adding complementary antioxidants (e.g., Vitamin E, stabilized Vitamin C) to the final formulation is highly recommended to protect the active from long-term oxidation.
  • Chelating Agents: EDTA or naturally derived chelators (e.g., Sodium Phytate) are recommended to ensure formula stability.

7. Safety & Regulatory

  • Safety Profile: High tolerability demonstrated in clinical use; suitable for sensitive skin. Non-phototoxic.
  • Claims: Supports acne-prone skin care, helps improve the appearance of blemish-prone skin, promotes clearer-looking skin, anti-aging, skin soothing.
  • Storage: Store in a cool, dry place, protected from direct light and heat. Keep container tightly closed.

8. Applications

  • Premium Anti-Aging Clear Serums & Hydrogels
  • Sensitive Skin Repair Formulations
  • Blemish-Care & Acne-Prone Skin Treatments
  • Brightening & Uneven Tone Correctors
  • Daytime Protective Skincare (Non-light-sensitizing)

Disclaimer: This document is for informational purposes for professional cosmetic formulators. The claims presented are cosmetic in nature and should be substantiated by final product testing.

PuriActives® PALMITOYL METHOXYTRYPTAMINE

Posted on by

Available in Pure Crystalline Powder & NanoActive® Water-Soluble Liquid Grades

1. PRODUCT IDENTIFICATION

  • Trade Name: PuriActives® PALMITOYL METHOXYTRYPTAMINE (Pure Powder Grade) / NanoActive® PALMITOYL METHOXYTRYPTAMINE (Water-Soluble Liquid Grade)
  • INCI Name (US/EU):

Pure Powder Grade: Palmitoyl Methoxytryptamine

NanoActive® Grade: Water, Glycerin, Phospholipids, Palmitoyl Methoxytryptamine, Caprylic/Capric Glyceride

  • Chemical Name (Active): N-[2-(5-methoxy-1H-indol-3-yl)ethyl]hexadecanamide
  • CAS Number (Active): 224422-91-3
  • Molecular Formula (Active): C₂₇H₄₄N₂O₂
  • Molecular Weight (Active): 428.66 g/mol
  • Chemical Structure: CH₃-(CH₂)₁₄-CO-NH-CH₂-CH₂-C₈H₄(OCH₃)NH

2. PRODUCT DESCRIPTION

PuriActives® Palmitoyl Methoxytryptamine is a high-purity, bio-mimetic lipid-alkaloid conjugate engineered to deliver profound neuro-cosmetic soothing and cellular anti-inflammatory benefits. By coupling the potent neuro-active molecule 5-methoxytryptamine (a direct analog and precursor of melatonin) with palmitic acid, this compound exhibits exceptional skin-penetration kinetics and lipid-membrane affinity.

To address the inherent solubility limitations of the pure lipophilic crystalline powder in water-based cosmetic architectures, PuriPharm offers NanoActive® Palmitoyl Methoxytryptamine. Utilizing state-of-the-art advanced nano-delivery technology, this grade encapsulates the active within a biomimetic phospholipid bilayer membrane (average particle size < 100 nm). This advanced delivery system transforms a highly lipophilic compound into a thermodynamic-stable, optically transparent, and water-dispersible active, dramatically boosting skin bioavailability and offering effortless formulation flexibility.

3. CORE MECHANISMS OF ACTION

A. Neurogenic Soothing via TRP Channel Modulation

Sensitive skin is characterized by hyper-excited sensory nerve endings. Palmitoyl Methoxytryptamine acts as a gentle, soothing modulator of neurogenic pathways. It targets transient receptor potential (TRP) channels, specifically mitigating the over-activation of TRPV1 (capsaicin receptor), which in turn suppresses sensations of burning, stinging, tightness, and itching.

B. Anti-Inflammaging & PPAR-α Activation

Similar to endogenous endocannabinoid-like molecules (such as Palmitoylethanolamide / PEA), Palmitoyl Methoxytryptamine serves as an agonist for the nuclear receptor PPAR-α (Peroxisome Proliferator-Activated Receptor Alpha). This activation triggers downstream anti-inflammatory cascades:

  • Inhibits the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α.
  • Suppresses mast cell degranulation, mitigating sudden skin redness and histamine-induced itchiness.

C. Melatonin Receptor Agonism & Circadian Repair

Because 5-methoxytryptamine is a direct deacetylation analog of melatonin (N-acetyl-5-methoxytryptamine), Palmitoyl Methoxytryptamine acts as a highly potent biomimetic agent for cutaneous melatonin receptors (MT1 and MT2). This direct agonism:

  • Resets and synchronizes the skin’s biological clock genes (such as CLOCK and PER1).
  • Enhances the skin’s endogenous defense against oxidative stress induced by ultraviolet (UV) radiation and blue light.
  • Accelerates nocturnal DNA repair and cell regeneration, restoring a radiant and rested complexion overnight.

D. Enhanced Bioavailability via Lipophilic Vectoring & Nano-Carrier Delivery

  • Pure Powder: Conjugation with palmitic acid increases the partition coefficient (log P ≈ 7.15), allowing the active to integrate seamlessly into the intercellular lipid matrix of the stratum corneum.
  • NanoActive® Liquid: The phospholipid membrane of the nano-carriers fuses directly with the lipid bilayers of the stratum corneum. This bypasses the rate-limiting barrier of intercellular lipid transport, creating a “depot effect” in the viable epidermis and accelerating cellular uptake of the active molecule.

4. TECHNICAL SPECIFICATIONS

[Grade A] PuriActives® PALMITOYL METHOXYTRYPTAMINE (Pure Powder)

[Grade B] NanoActive® PALMITOYL METHOXYTRYPTAMINE (Water-Soluble Liquid)

Microbiological Specifications (Both Grades)

  • Total Aerobic Plate Count: ≤ 100 CFU/g
  • Yeasts and Molds: ≤ 10 CFU/g
  • Pathogens (E. coli, S. aureus, P. aeruginosa): Negative/g

5. COSMETIC BENEFITS & CLINICAL CLAIMS

  • Instant Neuro-Soothing: Rapidly reduces sensory discomfort, itching, and neuro-sensitivity.
  • Anti-Redness & Erythema Control: Dampens micro-vascular reactivity and controls flushing in rosacea-prone skin.
  • Skin Barrier Recovery: Accelerates epidermal barrier repair and decreases trans-epidermal water loss (TEWL).
  • Intense Inflammaging Defense: Protects structural proteins (collagen and elastin) from enzymatic degradation caused by chronic low-grade inflammation.
  • Chronobiological Renewal: Aids in resetting skin repair rhythms, restoring a radiant and rested complexion overnight.

6. FORMULATION & PROCESSING GUIDELINES (PURE POWDER)

A. Recommended Usage Levels

  • Daily Soothing & Maintenance Creams: 0.05% – 0.2%
  • Intensive SOS / Post-Procedure Care: 0.2% – 0.5%

B. Solubility & Incorporation

  • Oil Phase: Soluble in hot cosmetic esters and lipids (e.g., Caprylic/Capric Triglyceride, Squalane, C12-15 Alkyl Benzoate) at 75°C – 80°C.
  • Water Phase: Insoluble in water.

C. Processing Temperature

● Stable at temperatures up to 85°C. It is recommended to dissolve the active in the oil phase before emulsification.

7. FORMULATION & PROCESSING GUIDELINES (NANOACTIVE® LIQUID)

A. Recommended Usage Levels

  • Daily Soothing Serums & Toners: 1.0% – 4.0% (Equivalent to 0.05% – 0.2% pure active)
  • High-Concentration Clinical Soothing Ampoules: 4.0% – 10.0% (Equivalent to 0.2% – 0.5% pure active)

B. Solubility & Incorporation

  • Water Phase: 100% dispersible in water. It yields an elegant, optically transparent solution, ideal for clear gel, serum, toner, and essence formulations.
  • Incorporation: Highly recommended to add to the water phase or post-emulsification phase during the cooling stage at temperatures below 40°C.

C. Processing Guidelines & Shear Sensitivity

● Avoid exposing NanoActive® grade to high-shear homogenization equipment (e.g., rotor-stator homogenizers) for prolonged periods, as extreme shear can disrupt the lipid vesicle bilayers. Use paddle stirring or gentle marine propellers to disperse.

D. pH Stability (NanoActive®)

● Optimum stability is observed within a pH range of 4.5 – 6.5.

8. STORAGE, SHELF LIFE & REGULATORY

● Storage Conditions: Store in the original, tightly sealed container.

  • Pure Powder: Keep in a cool, dry, and well-ventilated area, preferably refrigerated at 2°C – 8°C for long-term storage.
  • NanoActive® Liquid: Do not freeze. Store at 4°C – 25°C, protected from direct sunlight and heat.

● Shelf Life: 24 months from the date of manufacture when stored under prescribed conditions.

● Regulatory Compliance: Approved for use in cosmetics worldwide (including EU, USA, and China IECIC listing). Vegan-compliant, cruelty-free, and non-GMO.

Disclaimer: The information contained in this document is provided in good faith and is based on our current technical knowledge. Formulation results may vary depending on other raw materials and processing equipment used. It is the formulator’s responsibility to conduct final product safety and efficacy tests.

PuriActives® PALMITOYL TRYPTAMINE

Posted on by

Available in Pure Crystalline Powder & NanoActive® Water-Soluble Liquid Grades

1. PRODUCT IDENTIFICATION

  • Trade Name: PuriActives® PALMITOYL TRYPTAMINE (Pure Powder Grade) / NanoActive® PALMITOYL TRYPTAMINE (Water-Soluble Liquid Grade)

INCI Name (US/EU):

  • Pure Powder Grade: Palmitoyl Tryptamine
  • NanoActive® Grade: Water, Glycerin, Phospholipids, Palmitoyl Tryptamine, Caprylic/Capric Triglyceride
  • Chemical Name (Active): N-[2-(1H-indol-3-yl)ethyl]hexadecanamide
  • CAS Number (Active): 21469-15-8
  • Molecular Formula (Active): C₂₆H₄₂N₂O
  • Molecular Weight (Active): 398.63 g/mol
  • Chemical Structure: CH₃-(CH₂)₁₄-CO-NH-CH₂-CH₂-C₈H₅NH

2. PRODUCT DESCRIPTION

PuriActives® Palmitoyl Tryptamine is a high-purity, bio-mimetic lipid-alkaloid conjugate engineered to deliver profound neuro-cosmetic soothing and cellular anti-inflammatory benefits. By coupling the potent neuro-active molecule tryptamine with palmitic acid, this compound exhibits exceptional skin-penetration kinetics and lipid-membrane affinity.

To address the inherent solubility limitations of the pure lipophilic crystalline powder in water-based cosmetic architectures, PuriPharm offers NanoActive® Palmitoyl Tryptamine. Utilizing state-of-the-art advanced nano-delivery technology, this grade encapsulates the active within a biomimetic phospholipid bilayer membrane (average particle size < 100 nm). This advanced delivery system transforms a highly lipophilic compound into a thermodynamic-stable, optically transparent, and water-dispersible active, dramatically boosting skin bioavailability and offering effortless formulation flexibility.

3. CORE MECHANISMS OF ACTION

A. Neurogenic Soothing via TRP Channel Modulation

Sensitive skin is characterized by hyper-excited sensory nerve endings. Palmitoyl Tryptamine acts as a gentle, soothing modulator of neurogenic pathways. It targets transient receptor potential (TRP) channels, specifically mitigating the over-activation of TRPV1 (capsaicin receptor), which in turn suppresses sensations of burning, stinging, tightness, and itching.

B. Anti-Inflammaging & PPAR-α Activation

Similar to endogenous endocannabinoid-like molecules (such as Palmitoylethanolamide / PEA), Palmitoyl Tryptamine serves as an agonist for the nuclear receptor PPAR-α (Peroxisome Proliferator-Activated Receptor Alpha). This activation triggers downstream anti-inflammatory cascades:

  • Inhibits the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α.
  • Suppresses mast cell degranulation, mitigating sudden skin redness and histamine-induced itchiness.

C. Melatonin Pathway Synergy & Circadian Repair

Because tryptamine is an biochemical precursor in the melatonin and serotonin synthesis pathways, topical application of Palmitoyl Tryptamine supports the skin’s nocturnal repair mechanisms. It enhances the skin’s endogenous defense against oxidative stress induced by ultraviolet (UV) radiation and blue light, helping to maintain cellular homeostasis during sleep.

D. Enhanced Bioavailability via Lipophilic Vectoring & Nano-Carrier Delivery

  • Pure Powder: Conjugation with palmitic acid increases the partition coefficient (log P ≈ 6.83), allowing the active to integrate seamlessly into the intercellular lipid matrix of the stratum corneum.
  • NanoActive® Liquid: The phospholipid membrane of the nano-carriers fuses directly with the lipid bilayers of the stratum corneum. This bypasses the rate-limiting barrier of intercellular lipid transport, creating a “depot effect” in the viable epidermis and accelerating cellular uptake of the active molecule.

4. TECHNICAL SPECIFICATIONS

[Grade A] PuriActives® PALMITOYL TRYPTAMINE (Pure Powder)

[Grade B] NanoActive® PALMITOYL TRYPTAMINE (Water-Soluble Liquid)

Microbiological Specifications (Both Grades)

  • Total Aerobic Plate Count: ≤ 100 CFU/g
  • Yeasts and Molds: ≤ 10 CFU/g
  • Pathogens (E. coli, S. aureus, P. aeruginosa): Negative/g

5. COSMETIC BENEFITS & CLINICAL CLAIMS

  • Instant Neuro-Soothing: Rapidly reduces sensory discomfort, itching, and neuro-sensitivity.
  • Anti-Redness & Erythema Control: Dampens micro-vascular reactivity and controls flushing in rosacea-prone skin.
  • Skin Barrier Recovery: Accelerates epidermal barrier repair and decreases trans-epidermal water loss (TEWL).
  • Intense Inflammaging Defense: Protects structural proteins (collagen and elastin) from enzymatic degradation caused by chronic low-grade inflammation.
  • Chronobiological Renewal: Aids in resetting skin repair rhythms, restoring a radiant and rested complexion overnight.

6. FORMULATION & PROCESSING GUIDELINES (PURE POWDER)

A. Recommended Usage Levels

  • Daily Soothing & Maintenance Creams: 0.05% – 0.2%
  • Intensive SOS / Post-Procedure Care: 0.2% – 0.5%

B. Solubility & Incorporation

  • Oil Phase: Soluble in hot cosmetic esters and lipids (e.g., Caprylic/Capric Triglyceride, Squalane, C12-15 Alkyl Benzoate) at 75°C – 80°C.
  • Water Phase: Insoluble in water.

C. Processing Temperature

●Stable at temperatures up to 85°C. It is recommended to dissolve the active in the oil phase before emulsification.

7. FORMULATION & PROCESSING GUIDELINES (NANOACTIVE® LIQUID)

A. Recommended Usage Levels

  • Daily Soothing Serums & Toners: 1.0% – 4.0% (Equivalent to 0.05% – 0.2% pure active)
  • High-Concentration Clinical Soothing Ampoules: 4.0% – 10.0% (Equivalent to 0.2% – 0.5% pure active)

B. Solubility & Incorporation

  • Water Phase: 100% dispersible in water. It yields an elegant, optically transparent solution, ideal for clear gel, serum, toner, and essence formulations.
  • Incorporation: Highly recommended to add to the water phase or post-emulsification phase during the cooling stage at temperatures below 40°C.

C. Processing Guidelines & Shear Sensitivity

  • Avoid exposing NanoActive® grade to high-shear homogenization equipment (e.g., rotor-stator homogenizers) for prolonged periods, as extreme shear can disrupt the lipid vesicle bilayers. Use paddle stirring or gentle marine propellers to disperse.

D. pH Stability (NanoActive®)

  • Optimum stability is observed within a pH range of 4.5 – 6.5.

8. STORAGE, SHELF LIFE & REGULATORY

  • Storage Conditions: Store in the original, tightly sealed container.
  • Pure Powder: Keep in a cool, dry, and well-ventilated area, preferably refrigerated at 2°C – 8°C for long-term storage.
  • NanoActive® Liquid: Do not freeze. Store at 4°C – 25°C, protected from direct sunlight and heat.
  • Shelf Life: 24 months from the date of manufacture when stored under prescribed conditions.
  • Regulatory Compliance: Approved for use in cosmetics worldwide (including EU, USA, and China IECIC listing). Vegan-compliant, cruelty-free, and non-GMO.

Disclaimer: The information contained in this document is provided in good faith and is based on our current technical knowledge. Formulation results may vary depending on other raw materials and processing equipment used. It is the formulator’s responsibility to conduct final product safety and efficacy tests.